Skip to content
Biotechnology

Lithuanian Biotech Pioneer ‘Nando’ Embarks on Global Expansion With New Management Team and Innovative Production Line

Nando 2 mins read

"Nando", a leading Lithuanian-owned biotechnology company known for its groundbreaking work in developing microbiological products for agriculture, that helped to save up to 50M on fertilisers, announces a significant bolstering of its management team and an ambitious expansion of its biotechnological production line. This move is set to position "Nando" not just as a leader in Lithuania but as a formidable player on the international stage.

KAUNAS, LITHUANIA / ACCESSWIRE / May 7, 2024 / In a strategic enhancement of its management team, "Nando" welcomes four seasoned professionals, each bringing a wealth of experience from reputable organizations. Gytis Kubilius, with a solid background in management at "SEB" and "Citadele" banks; Mindaugas Navickas, previously International Sales Manager at "Teltonika Networks"; Arūnas Jusas, former General Manager at "Timac AGRO"; and Giedrė Mockienė, who served as HR Manager at UAB "Yara", are now integral parts of "Nando's" leadership, aiming to spearhead ambitious development projects.

To cater to the surging demand for microbiological alternatives to mineral fertilizers and plant protection products, "Nando" has invested about €3 million in a unique biotechnology line. This investment boosts production volume, enhances productivity, and ensures competitive pricing to meet the escalating market demand. With a technology that is currently patent-pending, "Nando" exports to over 20 countries, including Great Britain, Ukraine, Estonia, Kazakhstan, Latvia, Poland, Romania and beyond.

Justinas Taruška, CEO of "Nando", stated, "Our main goal is to feature a highly automated biotechnological production line. This will not only elevate the agro-biotechnology sector's value in Lithuania but also accelerate sustainable and economically viable agricultural technologies across Europe and other continents." The new production line is renowned for its unique microorganism purification technology, a rarity in the entire Baltic region. It promises an efficient production of stable, high-yield microbiological products in powder form, a technology with limited competition.

The inclusion of new management members, with their extensive international experience, underscores "Nando's" commitment to employee development and its focus on penetrating foreign markets, including Europe, North and South America, Asian and Africa countries. This strategic move coincides with the launch of the new production line for microbiological products.

Founded in 2007, "Nando" stands at the forefront of the biotech industry, developing and manufacturing microbiological products and chemical additives for agriculture. With one of Northern Europe's leading R&D centers and partnerships with global research institutions, "Nando" has introduced over 50 innovative products, vital to the agro, livestock. Currently, the company is intensifying its export activities, with operations spanning over 20 countries in Europe, North and South America, Asian and Africa. The "Nando Group" proudly employs more than 50 professionals dedicated to advancing global biotechnology solutions.

Contact Information:

Milda Gauliene
Marketing specialist
milda@nando.lt
+37066475297

SOURCE: Nando

.

View the original press release on newswire.com.

More from this category

  • Biotechnology, Business Company News
  • 24/07/2024
  • 10:53
Jane Morgan Management

LTR Pharma Ltd (ASX:LTP) Completes A$10.5 million Placement to Expedite Commercialisation of SPONTAN

Sydney, Australia – 24 July 2024 – LTR Pharma Limited (ASX: LTP) ("LTR Pharma" or "the Company"), a company focused on improving men’s health through the clinical development and commercialisation of an innovative nasal spray treatment for Erectile Dysfunction ("ED") called SPONTAN®, is pleased to announce the successful completion of a A$10.5 million share placement to sophisticated and new institutional investors. The placement received demand significantly above the A$10.5 million raised. Key Highlights: Successful Fundraising: LTR Pharma has raised A$10.5 million through a private placement at an issue price of A$0.73 per share, representing a 13.2% discount to the 30-day…

  • Contains:
  • Agriculture Farming Rural, Biotechnology
  • 23/07/2024
  • 15:56
La Trobe University

Nation’s food security tackled through new institute

La Trobe University is paving the way for Australian food security, with the establishment of a new institute that will expand cutting-edge agricultural research and innovation. The La Trobe Institute for Sustainable Agriculture and Food (LISAF) officially launched today (23 July), to undertake research and innovation across the agri-food-health chain, aiming to enhance profitability for producers while also improving product quality and choice for consumers. LISAF Director Professor Tony Bacic said a key component of the Institute’s “paddock to gut” research was to enhance plant functionality, enabling food and medicinal crops to be grown in innovative ways and with new…

  • Biotechnology, Medical Health Aged Care
  • 22/07/2024
  • 12:56
Illumina

Research into psychedelic medicines to treat anxiety wins ANS Illumina Neurogenomics Award 2024

Genomic technologies to discover biological markers, within the blood, that could predict patient response to psychedelic medicines such as psilocybin. MELBOURNE, AUSTRALIA, 22 July 2024 - Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the winner of the annual Australasian Neuroscience Society (ANS) Illumina Neurogenomics Research Award as Dr Andrew Gibbons from the Department of Psychiatry, School of Clinical Sciences at Monash Health. “Psilocybin, a chemical produced by hallucinogenic mushrooms, is a psychedelic medicine that has shown to meaningfully reduce symptoms of generalized anxiety during psychotherapy for patients. However, not all patients respond.…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.